Alpha 2.0
Login Register
» Authors » Manfred Hensel

Manfred Hensel

Explore the profile of Manfred Hensel including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 58
Citations 926
Followers 0
Related Specialties
Hematology
Oncology
General Medicine
Top 10 Co-Authors
Anthony D Ho
Axel Benner
Michael Hallek
Marcel Reiser
Mathias Witzens-Harig
Stephan Stilgenbauer
Peter Dreger
Hartmut Dohner
Michael Kneba
Raymonde Busch
Published In
Eur J Haematol
Blood
Leuk Lymphoma
Ann Hematol
Int J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial
Langerbeins P, Robrecht S, Nieper P, Cramer P, Furstenau M, Al-Sawaf O, et al.
J Clin Oncol . 2024 Nov; 43(4):392-402. PMID: 39602678
Purpose: The CLL12 trial reassesses the watch-and-wait consensus for early-stage chronic lymphocytic leukemia (CLL) in the context of targeted therapies. Methods: The German CLL Study Group conducted a randomized, double-blind,...
2.
CD8 CD28 regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
Kriegsmann K, Ton G, Awwad M, Benner A, Bertsch U, Besemer B, et al.
Leukemia . 2024 Jun; 38(7):1621-1625. PMID: 38830959
No abstract available.
3.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
Mai E, Goldschmid H, Miah K, Bertsch U, Besemer B, Hanel M, et al.
Lancet Haematol . 2024 Feb; 11(2):e101-e113. PMID: 38302221
Background: The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well...
4.
SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues
Buhler M, Lu J, Scheinost S, Nadeu F, Roos-Weil D, Hensel M, et al.
Leuk Res . 2021 May; 107:106608. PMID: 33979727
No abstract available.
5.
Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement
Weide R, Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn M, et al.
BMC Immunol . 2020 Jul; 21(1):39. PMID: 32600256
Background: The effects of intravenous immunoglobulin G replacement on perceived health and infection susceptibility of patients suffering from immunoglobulin G (IgG) deficiencies should be evaluated in a prospective analysis. Methods:...
6.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial
Cramer P, Tresckow J, Robrecht S, Bahlo J, Furstenau M, Langerbeins P, et al.
Haematologica . 2020 Feb; 106(2):543-554. PMID: 32107341
The introduction of targeted agents has revolutionized the treatment of chronic lymphocytic leukemia but only few patients achieve complete remissions and minimal residual disease negativity with ibrutinib monotherapy. This multicenter,...
7.
Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy
Furstenau M, Hopfinger G, Robrecht S, Fink A, Al-Sawaf O, Langerbeins P, et al.
Leukemia . 2019 Nov; 34(4):1177-1181. PMID: 31728057
No abstract available.
8.
Response to the letter to the Editor concerning our article "High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany"
Feiten S, Chakupurakal G, Feustel H, Maasberg M, Otremba B, Ehscheidt P, et al.
Support Care Cancer . 2019 Nov; 28(1):3-4. PMID: 31701271
No abstract available.
9.
Patients With Malignant Lymphoma and HIV Infection Experiencing Remission After First-Line Treatment Have an Excellent Prognosis
Kriegsmann K, Klee J, Hensel M, Buss E, Kriegsmann M, Cremer M, et al.
Clin Lymphoma Myeloma Leuk . 2019 Aug; 19(10):e581-e587. PMID: 31377211
Background: Malignant lymphoma is still the leading cause of death among AIDS-related diseases. Patients And Methods: We performed a retrospective analysis of 50 HIV-positive lymphoma patients. The median interval between...
10.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, et al.
BMC Cancer . 2019 May; 19(1):504. PMID: 31138244
Background: Despite major advances in therapy, multiple myeloma is still an incurable malignancy in the majority of patients. To increase survival, deeper remissions (i.e. CR) translating into longer PFS need...